Part 3/11:
The deregulation she's referencing includes shifts in regulatory policy, notably the appointment of a new head of the FTC who is more receptive to mergers and acquisitions (M&A). This policy environment is fostering a strategic price discovery process, encouraging pharma and biotech companies to partner or acquire firms within the genomic space. Many of these companies are poised to help fill a $300 billion revenue hole caused by patent expirations over the next five years. Wood views this as a perfect storm of opportunity that underscores the undervalued and misunderstood potential of AI-driven biotech applications.